Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 2, 2009, Pages 119-126

  Reinblatt, Shauna P ^a,b   Dosreis, Susan ^a   Walkup, John T ^a   Riddle, Mark A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; PLACEBO;

ADOLESCENT; ARTICLE; BEHAVIOR DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERACTIVITY; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANIA; PANIC; PREVALENCE; SEPARATION ANXIETY; SOCIAL PHOBIA;

ADOLESCENT; ANXIETY DISORDERS; CHILD; CHILD BEHAVIOR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUVOXAMINE; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS;

EID: 65249155373     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.040     Document Type: Article

References (25)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington (DC): The American Psychiatric Association, 1994.
2. Garland EJ, Baerg EA: Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol 11:181-186, 2001.
3. Gerber PE, Lynd LD: Selective serotonin-reuptake inhibitorinduced movement disorders. Ann Pharmacother 32:692-698, 1998.
4. Goodman WK, Murphy TK, Storch EA: Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology (Berl) 191:87-96, 2007.
5. Gualtieri CT, Johnson LG: Antidepressant side effects in children and adolescents. J Child Adolesc Psychopharmacol 16:147-157, 2006.
6. Hammad T. Review and Evaluation of Clinical Data: Relationship between psychotropic drugs and pediatric suicidality. Accessed at: www.fda.gov/ohrms/ dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf (accessed March 31, 2007).
7. Hoehn-Saric R, Harris GJ, Pearlson GD, Cox CS, Machlin SR, Carmargo EE: A fluoxetine-induced frontal lobe syndrome in an obsessive-compulsive patient. J Clin Psychiatry 52:131-133, 1991.
8. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
9. King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P, Scahill L: Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 30:179-186, 1991.
10. Labellarte M, Biederman J, Emslie G, Ferguson J, Khan A, Ruckle J, Sallee R, Riddle M: Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. J Am Acad Child Adolesc Psychiatry 43:1497-1505, 2004.
11. Leslie LK, Newman TB, Chesney PJ, Perrin JM: The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics 116:195-204, 2005.
12. Lipinski JF, Jr., Mallya G, Zimmerman P, Pope HG Jr: Fluoxetine-induced akathisia: Clinical and theoretical implications. J Clin Psychiatry 50:339-342, 1989.
13. Reinblatt SP, Riddle MA. Selective serotonin reuptake inhibitorinduced apathy: A pediatric case series. J Child Adolesc Psychopharmacol 16:227-233, 2006.
14. Research Units for Pediatric Psychopharmacology (RUPP) Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285, 2001.
15. Research Units for Pediatric Psychopharmacology Anxiety Study Group: The Pediatric Anxiety Rating Scale (PARS): Development and psychometric properties. J Am Acad Child Adolesc Psychiatry 41:1061-1069, 2002.
16. Riddle MA, King R, Hardin MT, Scahill L, Ort S, Chappell P, Rasmusson A, Leckman J: Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1:193-198, 1991.
17. Safer DJ, Zito JM: Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: Children versus adolescents. J Child Adolesc Psychopharmacol 16:159-169, 2006.
18. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1228-1231, 1983.
19. Teicher MH, Glod CA, Cole JO: Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 8:186-212, 1993.
20. Walkup J, Labellarte M: Complications of SSRI treatment. J Child Adolesc Psychopharmacol 11:1-4, 2001.
21. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363:1341-1345, 2004.
22. Wilens TE, Wyatt D, Spencer TJ: Disentangling disinhibition. J Am Acad Child Adolesc Psychiatry 37:1225-1227, 1998.
23. Wilens TE, Biederman J, Kwon A, Chase R, Greenberg L, Mick E, Spencer TJ: A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 13:143-152, 2003.
24. Wong IC, Besag FM, Santosh PJ, Murray ML: Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Safety 27:991-1000, 2004.
25. Zito JM, Safer DJ, dosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MA: Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med 157:17-25, 2003.